MetLife Stock Hits New 52-Week High (MET)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- MetLife (NYSE: MET) hit a new 52-week high Wednesday as it is currently trading at $41.22, above its previous 52-week high of $41.21 with 4.4 million shares traded as of 3:36 p.m. ET. Average volume has been 9.3 million shares over the past 30 days.

MetLife has a market cap of $44.69 billion and is part of the financial sector and insurance industry. Shares are up 23.8% year to date as of the close of trading on Tuesday.

MetLife, Inc., through its subsidiaries, provides insurance, annuities, and employee benefit programs in the United States, Japan, Latin America, the Middle East, Asia, and Europe. The company has a P/E ratio of 34.2, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates MetLife as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, revenue growth and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full MetLife Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations